Trials / Completed
CompletedNCT01096511
Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)
Clinical Effectiveness and Safety Study of Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,001 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from a cIAI and take at least one dose of Moxifloxacin infusion.The primary objective is to define the types of cIAI infections that require Moxifloxacin i.v. therapy in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Moxifloxacin (Avelox, BAY12-8039) | The treatment with Moxifloxacin 400 mg infusion should comply with the recommendations written in the local product information. The decision about the treatment with Moxifloxacin as well as the duration of treatment is solely up to the attending physician. |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2010-03-31
- Last updated
- 2013-06-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01096511. Inclusion in this directory is not an endorsement.